Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
173.53-1.27 (-0.73%)
At close: 4:00 PM EDT

169.52 -4.01 (-2.31%)
Pre-Market: 8:57 AM EDT

People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close174.80
Bid169.76 x 200
Ask170.00 x 100
Day's Range172.83 - 174.42
52wk Range131.43 - 176.85
1y Target EstN/A
Market Cap129.86B
P/E Ratio (ttm)17.76
Avg Vol (3m)2,847,721
Dividend & Yield4.00 (2.29%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Reuters11 minutes ago

    Amgen's multiple myeloma drug fails study in new patients

    Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, did not surpass Takeda Pharmaceutical Co Ltd's Velcade in a head-to-head late-stage study in previously untreated patients. The U.S. Food and Drug Administration has already approved Kyprolis for patients with relapsed or refractory multiple myeloma who have previously undergone one or more treatments. The latest study tested a regimen of Kyprolis against Velcade in patients who also received the chemothereutic agent melphalan and the immunosuppressant prednisone, and were deemed ineligible for stem-cell transplants.

  • Biosimilars in Limelight on FDA Approval of Amgen Drug
    Zacks47 minutes ago

    Biosimilars in Limelight on FDA Approval of Amgen Drug

    Biosimilars are gaining pace with new approvals and formulary coverage.

  • 24/7 Wall St.1 hour ago

    Short Sellers Increase Bets in Major Biotechs

    The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.